LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Clinical and cost-effectiveness of PCF versus ACD in the treatment of cervical brachialgia (FORVAD trial).

    Thomson, Simon / Ainsworth, Gemma / Selvanathan, Senthil / Brown, Sarah / Croft, Julie / Kelly, Rachel / Mujica-Mota, Ruben / Rousseau, Nikki / Higham, Ruchi / Stocken, Deborah

    British journal of neurosurgery

    2024  Volume 38, Issue 1, Page(s) 141–148

    Abstract: Background: Cervical radiculopathy occurs when a nerve root is compressed in the spine, if symptoms fail to resolve after 6 weeks surgery may be indicated. Anterior Cervical Discectomy (ACD) is the commonest procedure, Posterior Cervical Foraminotomy ( ... ...

    Abstract Background: Cervical radiculopathy occurs when a nerve root is compressed in the spine, if symptoms fail to resolve after 6 weeks surgery may be indicated. Anterior Cervical Discectomy (ACD) is the commonest procedure, Posterior Cervical Foraminotomy (PCF) is an alternative that avoids the risk of damage to anterior neck structures. This prospective, Phase III, UK multicentre, open, individually randomised controlled trial was performed to determine whether PCF is superior to ACD in terms of improving clinical outcome as measured by the Neck Disability Index (NDI) 52 weeks post-surgery.
    Method: Following consent to participate and collection of baseline data, subjects with cervical brachialgia were randomised to ACD or PCF in a 1:1 ratio on the day of surgery. Clinical outcomes were assessed on day 1 and patient reported outcomes on day 1 and weeks 6, 12, 26, 39 and 52 post-operation. A total of 252 participants were planned to be randomised. Statistical analysis was limited to descriptive statistics. Health economic outcomes were also described.
    Results: The trial was closed early (n = 23). Compared to baseline, the median (interquartile range (IQR)) NDI score at 52 weeks reduced from 44.0 (36.0, 62.0) to 25.3 (20.0, 42.0) in the PCF group and increased from 35.6 (34.0, 44.0) to 45.0 (20.0, 57.0) in the ACD group. ACD may be associated with more swallowing, voice and other complications and was more expensive; neck and arm pain scores were similar.
    Conclusions: The trial was closed early, therefore no definitive conclusions on clinical or cost-effectiveness could be made.
    MeSH term(s) Humans ; Foraminotomy/methods ; Treatment Outcome ; Cost-Benefit Analysis ; Prospective Studies ; Cervical Vertebrae/surgery ; Spinal Fusion/methods ; Diskectomy/adverse effects ; Diskectomy/methods ; Radiculopathy/surgery
    Language English
    Publishing date 2024-01-27
    Publishing country England
    Document type Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase III ; Journal Article
    ZDB-ID 639029-8
    ISSN 1360-046X ; 0268-8697
    ISSN (online) 1360-046X
    ISSN 0268-8697
    DOI 10.1080/02688697.2023.2267119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.

    Taprogge, Jan / Abreu, Carla / Yusuf, Siraj / Ainsworth, Gemma / Phillip, Rachel H / Gear, Jonathan I / Gregory, Rebecca / Leek, Francesca / Murray, Iain / Coulson, Amy B / Brown, Sarah R / Du, Yong / Newbold, Kate / Wadsley, Jonathan / Flux, Glenn D

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2023  Volume 64, Issue 7, Page(s) 1125–1130

    Abstract: Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A ... ...

    Abstract Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A personalized approach to treatment, based on the absorbed radiation doses delivered and using treatments to enhance RAI uptake, has not yet been developed.
    MeSH term(s) Humans ; Thyroid Neoplasms/diagnostic imaging ; Thyroid Neoplasms/radiotherapy ; Thyroid Neoplasms/drug therapy ; Iodine Radioisotopes/therapeutic use ; Radiometry ; Diagnostic Imaging
    Chemical Substances Iodine Radioisotopes
    Language English
    Publishing date 2023-04-28
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.122.264913
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.

    Wadsley, Jon / Ainsworth, Gemma / Coulson, Amy Beth / Garcez, Kate / Moss, Laura / Newbold, Kate / Farnell, Kate / Swain, Jayne / Howard, Helen / Beasley, Matthew / Weaver, Andrew / Wood, Katie / Marshall, Jennifer / Griffin, Matthew / Pascoe, Abigail / Du, Yong / Taprogge, Jan / Flux, Glenn / Brown, Sarah

    Thyroid : official journal of the American Thyroid Association

    2023  Volume 33, Issue 9, Page(s) 1119–1123

    MeSH term(s) Humans ; Iodine Radioisotopes/therapeutic use ; Iodine/therapeutic use ; Thyroid Neoplasms/radiotherapy ; Thyroid Neoplasms/drug therapy ; Adenocarcinoma ; Antineoplastic Agents/therapeutic use
    Chemical Substances Iodine Radioisotopes ; Iodine (9679TC07X4) ; Antineoplastic Agents
    Language English
    Publishing date 2023-09-01
    Publishing country United States
    Document type Clinical Trial, Phase II ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1086044-7
    ISSN 1557-9077 ; 1050-7256
    ISSN (online) 1557-9077
    ISSN 1050-7256
    DOI 10.1089/thy.2022.0707
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Effect of AZD4017, a Selective 11β-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia.

    Abbas, Afroze / Schini, Marian / Ainsworth, Gemma / Brown, Sarah R / Oughton, Jamie / Crowley, Rachel K / Cooper, Mark S / Fairclough, Rebecca J / Eastell, Richard / Stewart, Paul M

    The Journal of clinical endocrinology and metabolism

    2022  Volume 107, Issue 7, Page(s) 2026–2035

    Abstract: Context: The causative link between circulating glucocorticoid excess and osteoporosis is well-established. The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which increases local cortisol production, is expressed in human osteoblasts and ... ...

    Abstract Context: The causative link between circulating glucocorticoid excess and osteoporosis is well-established. The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which increases local cortisol production, is expressed in human osteoblasts and its activity increases with age.
    Objective: We hypothesized that local 11β-HSD1 might mediate an age-related decrease in bone formation and that selective 11β-HSD1 inhibition may enhance bone formation.
    Methods: A dual-center, phase II, randomized, double-blind, placebo-controlled trial of 90 days' treatment with AZD4017 (a selective 11β-HSD1 inhibitor) was conducted in 55 postmenopausal women with osteopenia. Participants received 400 mg oral AZD4017 twice daily vs matched placebo over 90 days. The primary outcome measure was the impact on the bone formation marker osteocalcin. Secondary objectives included correlation with 11β-HSD1 activity.
    Results: At 90 days, osteocalcin levels did not differ between treatment groups: active (mean 22.3 [SD 8.6] ng/mL, n = 22) and placebo (21.7 [SD 9.2] ng/mL, n = 24), with a baseline-adjusted treatment effect of 0.95 (95% CI: -2.69, 4.60). The results from the urinary [THF + alloTHF]/THE ratio (index of 11β-HSD1 activity) and the urinary cortisol/cortisone ratio (index of 11β-HSD2 activity) confirmed a > 90% inhibition of 11β-HSD1 but no change in activity of 11β-HSD2.
    Conclusion: This trial demonstrates that AZD4017 selectively inhibits 11β-HSD1 activity in vivo in a safe and reversible manner. Following 90 days of treatment, there is no effect on bone formation, indicating that the relative impairment of bone mineral density in postmenopausal women is not mediated by local intracellular production of cortisol under normal physiological concentrations.
    MeSH term(s) 11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors ; 11-beta-Hydroxysteroid Dehydrogenase Type 2/metabolism ; Bone Diseases, Metabolic/drug therapy ; Bone Remodeling ; Female ; Glucocorticoids ; Humans ; Hydrocortisone ; Niacinamide/analogs & derivatives ; Niacinamide/therapeutic use ; Osteocalcin ; Piperidines/therapeutic use ; Postmenopause
    Chemical Substances 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid ; Glucocorticoids ; Piperidines ; Osteocalcin (104982-03-8) ; Niacinamide (25X51I8RD4) ; 11-beta-Hydroxysteroid Dehydrogenase Type 1 (EC 1.1.1.146) ; 11-beta-Hydroxysteroid Dehydrogenase Type 2 (EC 1.1.1.146) ; Hydrocortisone (WI4X0X7BPJ)
    Language English
    Publishing date 2022-03-11
    Publishing country United States
    Document type Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgac100
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Posterior cervical foraminotomy versus anterior cervical discectomy for Cervical Brachialgia: the FORVAD RCT.

    Thomson, Simon / Ainsworth, Gemma / Selvanathan, Senthil / Kelly, Rachel / Collier, Howard / Mujica-Mota, Ruben / Talbot, Rebecca / Brown, Sarah Tess / Croft, Julie / Rousseau, Nikki / Higham, Ruchi / Al-Tamimi, Yahia / Buxton, Neil / Carleton-Bland, Nicholas / Gledhill, Martin / Halstead, Victoria / Hutchinson, Peter / Meacock, James / Mukerji, Nitin /
    Pal, Debasish / Vargas-Palacios, Armando / Prasad, Anantharaju / Wilby, Martin / Stocken, Deborah

    Health technology assessment (Winchester, England)

    2023  Volume 27, Issue 21, Page(s) 1–228

    Abstract: Background: Posterior cervical foraminotomy and anterior cervical discectomy are routinely used operations to treat cervical brachialgia, although definitive evidence supporting superiority of either is lacking.: Objective: The primary objective was ... ...

    Abstract Background: Posterior cervical foraminotomy and anterior cervical discectomy are routinely used operations to treat cervical brachialgia, although definitive evidence supporting superiority of either is lacking.
    Objective: The primary objective was to investigate whether or not posterior cervical foraminotomy is superior to anterior cervical discectomy in improving clinical outcome.
    Design: This was a Phase III, unblinded, prospective, United Kingdom multicentre, parallel-group, individually randomised controlled superiority trial comparing posterior cervical foraminotomy with anterior cervical discectomy. A rapid qualitative study was conducted during the close-down phase, involving remote semistructured interviews with trial participants and health-care professionals.
    Setting: National Health Service trusts.
    Participants: Patients with symptomatic unilateral cervical brachialgia for at least 6 weeks.
    Interventions: Participants were randomised to receive posterior cervical foraminotomy or anterior cervical discectomy. Allocation was not blinded to participants, medical staff or trial staff. Health-care use from providing the initial surgical intervention to hospital discharge was measured and valued using national cost data.
    Main outcome measures: The primary outcome measure was clinical outcome, as measured by patient-reported Neck Disability Index score 52 weeks post operation. Secondary outcome measures included complications, reoperations and restricted American Spinal Injury Association score over 6 weeks post operation, and patient-reported Eating Assessment Tool-10 items, Glasgow-Edinburgh Throat Scale, Voice Handicap Index-10 items, PainDETECT and Numerical Rating Scales for neck and upper-limb pain over 52 weeks post operation.
    Results: The target recruitment was 252 participants. Owing to slow accrual, the trial closed after randomising 23 participants from 11 hospitals. The qualitative substudy found that there was support and enthusiasm for the posterior cervical FORaminotomy Versus Anterior cervical Discectomy in the treatment of cervical brachialgia trial and randomised clinical trials in this area. However, clinical equipoise appears to have been an issue for sites and individual surgeons. Randomisation on the day of surgery and processes for screening and approaching participants were also crucial factors in some centres. The median Neck Disability Index scores at baseline (pre surgery) and at 52 weeks was 44.0 (interquartile range 36.0-62.0 weeks) and 25.3 weeks (interquartile range 20.0-42.0 weeks), respectively, in the posterior cervical foraminotomy group (
    Conclusions: The data suggest that posterior cervical foraminotomy is associated with better outcomes, fewer complications and lower costs, but the trial recruited slowly and closed early. Consequently, the trial is underpowered and definitive conclusions cannot be drawn. Recruitment was impaired by lack of individual equipoise and by concern about randomising on the day of surgery. A large prospective multicentre trial comparing anterior cervical discectomy and posterior cervical foraminotomy in the treatment of cervical brachialgia is still required.
    Trial registration: This trial is registered as ISRCTN10133661.
    Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in
    MeSH term(s) Humans ; Foraminotomy ; State Medicine ; Neck Pain ; Prospective Studies ; Diskectomy ; Cost-Benefit Analysis ; Quality of Life
    Language English
    Publishing date 2023-11-06
    Publishing country England
    Document type Randomized Controlled Trial ; Multicenter Study ; Clinical Trial, Phase III ; Journal Article
    ZDB-ID 2006765-3
    ISSN 2046-4924 ; 1366-5278
    ISSN (online) 2046-4924
    ISSN 1366-5278
    DOI 10.3310/OTOH7720
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

    Vasudev, Naveen S / Ainsworth, Gemma / Brown, Sarah / Pickering, Lisa / Waddell, Tom / Fife, Kate / Griffiths, Richard / Sharma, Anand / Katona, Eszter / Howard, Helen / Velikova, Galina / Maraveyas, Anthony / Brown, Janet / Pezaro, Carmel / Tuthill, Mark / Boleti, Ekaterini / Bahl, Amit / Szabados, Bernadett / Banks, Rosamonde E /
    Brown, Joanne / Venugopal, Balaji / Patel, Poulam / Jain, Ankit / Symeonides, Stefan N / Nathan, Paul / Collinson, Fiona J / Powles, Thomas

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 42, Issue 3, Page(s) 312–323

    Abstract: Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether ... ...

    Abstract Purpose: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether administering IPI once every 12 weeks (modified), instead of once every 3 weeks (standard), in combination with NIVO, is associated with a favorable toxicity profile.
    Methods: Treatment-naïve patients with clear-cell aRCC were randomly assigned 2:1 to receive four doses of modified or standard IPI, 1 mg/kg, in combination with NIVO (3 mg/kg). The primary end point was the proportion of patients with a grade 3-5 treatment-related adverse event (trAE) among those who received at least one dose of therapy. The key secondary end point was 12-month progression-free survival (PFS) in the modified arm compared with historical sunitinib control. The study was not designed to formally compare arms for efficacy.
    Results: Between March 2018 and January 2020, 192 patients (69.8% intermediate/poor-risk) were randomly assigned and received at least one dose of study drug. The incidence of grade 3-5 trAEs was significantly lower among participants receiving modified versus standard IPI (32.8%
    Conclusion: Rates of grade 3-5 trAEs were significantly lower in patients receiving modified versus standard IPI. Although 12-month PFS did not meet the prespecified efficacy threshold compared with historical control, informal comparison of treatment groups did not suggest any reduction in efficacy with the modified schedule.
    MeSH term(s) Humans ; Nivolumab/therapeutic use ; Ipilimumab ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology
    Chemical Substances Nivolumab (31YO63LBSN) ; Ipilimumab
    Language English
    Publishing date 2023-11-06
    Publishing country United States
    Document type Randomized Controlled Trial ; Clinical Trial, Phase II ; Journal Article
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.00236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.

    Buckley, Hannah L / Collinson, Fiona J / Ainsworth, Gemma / Poad, Heather / Flanagan, Louise / Katona, Eszter / Howard, Helen C / Murden, Geraldine / Banks, Rosamonde E / Brown, Joanne / Velikova, Galina / Waddell, Tom / Fife, Kate / Nathan, Paul D / Larkin, James / Powles, Thomas / Brown, Sarah R / Vasudev, Naveen S

    BMC cancer

    2019  Volume 19, Issue 1, Page(s) 1102

    Abstract: Background: The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for ... ...

    Abstract Background: The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC) based on recent phase III data. Combining ipilimumab with nivolumab increases rates of grade 3 and 4 toxicity compared with nivolumab alone, and the optimal scheduling of these agents when used together remains unknown. The aim of the PRISM study is to assess whether less frequent dosing of ipilimumab (12-weekly versus 3-weekly), in combination with nivolumab, is associated with a favourable toxicity profile without adversely impacting efficacy.
    Methods: The PRISM trial is a UK-based, open label, multi-centre, phase II, randomised controlled trial. The trial population consists of patients with untreated locally advanced or metastatic clear cell RCC, and aims to recruit 189 participants. Participants will be randomised on a 2:1 basis in favour of a modified schedule of 4 doses of 12-weekly ipilimumab versus a standard schedule of 4 doses of 3-weekly ipilimumab, both in combination with standard nivolumab. The proportion of participants experiencing a grade 3 or 4 adverse reaction within 12 months forms the primary endpoint of the study, but with 12-month progression free survival a key secondary endpoint. The incidence of all adverse events, discontinuation rates, overall response rate, duration of response, overall survival rates and health related quality of life will also be analysed as secondary endpoints. In addition, the potential of circulating and tissue-based biomarkers as predictors of therapy response will be explored.
    Discussion: The combination of nivolumab with ipilimumab is active in patients with mRCC. Modifying the frequency of ipilimumab dosing may mitigate toxicity rates and positively impact quality of life without compromising efficacy, a hypothesis being explored in other tumour types such as non-small cell lung cancer. The best way to give this combination to patients with mRCC must be similarly established.
    Trial registration: PRISM is registered with ISRCTN (reference ISRCTN95351638, 19/12/2017).
    Trial status: At the time of submission, PRISM is open to recruitment and data collection is ongoing.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/immunology ; Carcinoma, Renal Cell/pathology ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Ipilimumab/administration & dosage ; Ipilimumab/adverse effects ; Male ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology ; Quality of Life ; Treatment Outcome
    Chemical Substances CTLA-4 Antigen ; CTLA4 protein, human ; Ipilimumab ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2019-11-14
    Publishing country England
    Document type Clinical Trial, Phase II ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-019-6273-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top